Citius Oncology, Inc. CTOR Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s deferred tax assets?
- Citius Oncology, Inc. (CTOR) reported deferred tax assets of $2.82M in Q1 2026.
- How has Citius Oncology, Inc.'s deferred tax assets changed year-over-year?
- Citius Oncology, Inc.'s deferred tax assets increased by 24.9% year-over-year, from $2.26M to $2.82M.
- What is the long-term trend for Citius Oncology, Inc.'s deferred tax assets?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s deferred tax assets has grown at a 37.2% compound annual growth rate (CAGR), from $5.08M to $9.55M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.